Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Tech for Efficiency: Applications and Apparatuses to Accomplish More - 2Russia Creates New Military Branch Dedicated To Drone Warfare
- 3Iran war triggering Easter staycation boom
- 4Discovering a sense of harmony: Individual Accounts of Reflection and Care
- 5Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
- Tech for Learning: Online Courses and Instructive Apparatuses
- 2023's Best 10 Cell phone Advancements You Can't Miss
- AbbVie plans to build out its presence in obesity market
- Step by step instructions to Keep up with Ideal Oral Cleanliness at Home
- Experts who once backed 'shaken baby' science now fight to free imprisoned caregivers
- Ways to track down the Right Criminal Legal counselor
- Insurance warning signs in doctors’ offices might discourage patients from speaking openly about their health
- Palestinians forced from West Bank refugee camps left in limbo as Israeli demolitions go on
- China resumes flights to North Korea after a six-year pause
